MC1R is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-04-16. Numbers and descriptions here follow the published literature rather than marketing material.
Melanotan-2 is a synthetic linear peptide built from seven amino acids arranged in a short chain. Its sequence is commonly written as Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-NH2, which includes a modified N-terminus and an amidated C-terminus. The molecule belongs to the melanocortin family and acts as a receptor agonist. Structural features such as the D-phenylalanine residue and the Nle substitution are associated with increased stability against enzymatic degradation relative to the natural parent peptide.
The compound emerged from research programs in the 1980s that examined analogues of alpha-melanocyte-stimulating hormone for pigmentation and photoprotection. Investigators modified the native sequence to extend activity duration and potency. A related analogue, afamelanotide, was developed within the same broad line of inquiry and eventually gained approval in certain jurisdictions for a rare light-sensitivity condition. Melanotan-2 itself did not progress through the same regulatory route and has no approved therapeutic indication.
The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H69N15O9 | Free base; salt forms differ |
| Molecular weight | Approximately 1024 g/mol | Calculated for the free base |
| Appearance | White to off-white powder | Typically supplied as a lyophilised solid |
| Solubility | Soluble in water and polar solvents | Poorly soluble in non-polar solvents |
| Typical storage | -20 degrees Celsius, dry, protected from light | Refers to the solid form |
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
The peptide acts as a non-selective agonist at melanocortin receptors, showing affinity for MC1R, MC3R, MC4R and MC5R. Activation of MC1R on melanocytes drives the conversion of tyrosine into melanin and shifts production toward the darker eumelanin form. MC4R signalling in the central nervous system is linked to appetite and energy balance, which helps explain why reduced food intake appeared in early human studies. Effects on MC4R and on vascular tone also account for the erectile responses recorded as unexpected findings in those same trials.
Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.
Research interest has centred on photoprotection and pigmentation, with a smaller body of work on appetite and sexual function. Published human data remain limited to small, frequently uncontrolled studies, and the compound has never received marketing approval from a national medicines regulator. Most laboratory work treats it as a pharmacological tool for probing melanocortin signalling in cell culture or animal models. Whether pigmentation changes observed in people translate into measurable protection against ultraviolet-induced DNA damage remains an open question.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, the naturally occurring peptide involved in pigmentation signalling. Its sequence is conventionally written as Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, with a lactam bridge joining the aspartate side chain to the lysine side chain. The empirical formula is C50H69N15O9 and the monoisotopic mass lies near 1023.5 daltons. N-terminal acetylation and the D-configured phenylalanine both increase resistance to enzymatic breakdown compared with the parent hormone.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.
== Sensitivity == Depending on the analyte, an ECD can be 10-1000 times more sensitive than a flame ionization detector (FID), and one million times more sensitive than a thermal conductivity detector (TCD). An ECD has a limited dynamic range and finds its greatest application in analysis of halogenated compounds. The detection limit for electron capture detectors is 5 femtograms per second (fg/s) and the detector commonly exhibits a 10,000-fold linear range. This made it possible to detect halogenated compounds such as pesticides and CFCs, even at levels of only one part per trillion (ppt), thus revolutionizing our understanding of the atmosphere and pollutants.
Until recently, it was believed that the earliest ancient Egyptian mummies were created naturally due to the environment in which they were buried. In 2014, an 11-year study by the University of York, Macquarie University and the University of Oxford suggested that artificial mummification occurred 1,500 years earlier than first thought. This was confirmed in 2018, when tests on a 5,600-year-old mummy in Turin revealed that it had been deliberately mummified using linen wrappings and embalming oils made from conifer resin and aromatic plant extracts. The preservation of the dead had a profound effect on ancient Egyptian religion. Mummification was an integral part of the rituals for the dead beginning as early as the 2nd dynasty (about 2800 BC). Egyptians saw the preservation of the body after death as an important step to living well in the afterlife. As Egypt gained more prosperity, burial practices became a status symbol for the wealthy as well. This cultural hierarchy led to the creation of elaborate tombs, and more sophisticated methods of embalming. By the 4th dynasty (about 2600 BC) Egyptian embalmers began to achieve "true mummification" through a process of evisceration. Much of this early experimentation with mummification in Egypt is unknown. The few documents that directly describe the mummification process date to the Greco-Roman period. The majority of the papyri that have survived only describe the ceremonial rituals involved in embalming, not the actual surgical processes involved.
Newsom campaigned on reducing the cost of health care and increasing access. He also indicated his support for creating a universal state health-care system. The budget passed in June 2019 expanded eligibility for Medi-Cal from solely undocumented minor children to undocumented young adults from ages 19 to 25. In 2021, Newsom signed legislation expanding Medi-Cal eligibility to undocumented residents over age 50. On June 30, 2022, he signed a $307.9 billion state budget that "pledges to make all low-income adults eligible for the state's Medicaid program by 2024 regardless of their immigration status." This budget would make California the first U.S. state to guarantee healthcare to all low-income undocumented immigrants, at a cost of $2.7 billion per year. Newsom was criticized in early 2022 for walking back from his support for universal health care and not supporting CalCare, Assembly Bill 1400, which would have instituted single-payer healthcare in California; critics suggested that opposition from business interests, which had donated large sums to Newsom and his party, had swayed his opinion. On July 6, 2022, Newsom signed Senate Bill 184, which established the Office of Health Care Affordability, with the stated goal to "develop data-informed policies and enforceable cost targets, with the ultimate goal of containing health care costs". In August 2022, Newsom vetoed Senate Bill 57 which sought to authorize jurisdictions to approve supervised injection sites. Newsom signed The Zacky Bill. In October 2023, Newsom vetoed a bill to cap co-pays for insulin at $35.
We Happy Few has been said by some to be a cross between video games series BioShock, Fallout and Don't Starve, and novels Brave New World and Nineteen Eighty-Four. The main characters were also seen as amalgamations from these types of works: Arthur as a mix of Winston Smith from Nineteen Eighty-Four and Sam Lowry from Brazil, while Uncle Jack is seen as a mix of Jack Nicholson's Joker from Batman and Lewis Prothero from V for Vendetta. The developers commented on difficulties distinguishing the game from BioShock in the public eye, and though Provost said he was "flattered" by the comparison, he argued it was never a "prime influencer". Describing the meaning behind the story, Alex Epstein was quoted as saying "We Happy Few is inspired by, among other things, prescription drug culture — the idea that no one should have to be sad if they can pop a pill and fix it. It's also about Happy Facebook culture: no one shares their bad news because it would bring everyone down. As a culture, we no longer value sadness."
Sources: en.wikipedia.org
Fragments 1, 2, and 3 were reacted with each other to deliver epothilone B in an approach including Wittig reaction, aldol reaction, and Yamaguchi esterification (Figure 3). Preparative thin-layer chromatography was used to separate the diastereomers.
Insertions add one or more extra nucleotides into the DNA. They are usually caused by transposable elements, or errors during replication of repeating elements. Insertions in the coding region of a gene may alter splicing of the mRNA (splice site mutation), or cause a shift in the reading frame (frameshift), both of which can significantly alter the gene product. Insertions can be reversed by excision of the transposable element. Deletions remove one or more nucleotides from the DNA. Like insertions, these mutations can alter the reading frame of the gene. In general, they are irreversible: Though exactly the same sequence might, in theory, be restored by an insertion, transposable elements able to revert a very short deletion (say 1–2 bases) in any location either are highly unlikely to exist or do not exist at all. Substitution mutations, often caused by chemicals or malfunction of DNA replication, exchange a single nucleotide for another. These changes are classified as transitions or transversions. Most common is the transition that exchanges a purine for a purine (A ↔ G) or a pyrimidine for a pyrimidine, (C ↔ T). A transition can be caused by nitrous acid, base mispairing, or mutagenic base analogues such as BrdU. Less common is a transversion, which exchanges a purine for a pyrimidine or a pyrimidine for a purine (C/T ↔ A/G). An example of a transversion is the conversion of adenine (A) into a cytosine (C). Point mutations are modifications of single base pairs of DNA or other small base pairs within a gene.
More New York City Police Department (NYPD) officers were added, and District Attorney Robert Morgenthau agreed to process arrests in Bryant Park more quickly. By 1978, public perception of Bryant Park's safety was slightly better than in previous years, though drug dealers still frequented the park after office workers had gone back to work following their lunch breaks. Furthermore, NYPD officers initially declined to arrest drug users who were nonviolent. Starting in 1979, a coordinated program of amenities, including book and flower markets, landscape improvements, and entertainment activities, was initiated by a parks advocacy group called the Parks Council. Though the Parks Council's activities became popular, drug use and small crimes were still common within the park through the early 1980s. After a group of undercover NYPD officers were stationed in the park starting in 1980, they had made 400 drug-related arrests within six months.
=== Co–Coo === Philip Cohen FRS (b. 1945). At the University of Dundee known primarily for work on protein phosphorylation and ubiquitinylation. Stanley Cohen (1922–2020). American biochemist at Vanderbilt University. Nobel Prize in Physiology or Medicine (1986). Edwin Joseph Cohn (1892–1953). American protein chemist at Harvard, known for studies on blood and the physical chemistry of protein. Author, with John Edsall of Proteins, Amino Acids and Peptides, a very influential book. Member Natl. Acad. Sci. USA. Mildred Cohn (1913–2009). American biochemist, at the University of Pennsylvania, pioneer in the use of nuclear magnetic resonance to study enzyme reactions. Waldo Cohn (1910–1999). American biochemist at Oak Ridge National Laboratory, known for developing techniques for separating isotopes. Linda Columbus (active from 2002). American chemist at the University of Virginia known for work on membrane proteins. Sidney Colowick (1916–1985). American biochemist at Vanderbilt University and founding editor of Methods in Enzymology. Member Natl. Acad. Sci. USA. Minor J. Coon (1921–2018). American biochemist at the University of Michigan, Ann Arbor, discoverer of 3-hydroxy-3-methylglutaryl-CoA.
== Background == MAAs are widespread in the microbial world and have been reported in many microorganisms including heterotrophic bacteria, cyanobacteria, microalgae, ascomycetous and basidiomycetous fungi, as well as some multicellular organisms such as macroalgae and marine animals. Most research done on MAAs is on their light absorbing and radiation protecting properties. The first thorough description of MAAs was done in cyanobacteria living in a high UV radiation environment. The major unifying characteristic among all MAAs is UV light absorption. All MAAs absorb UV light that can be destructive to biological molecules (DNA, proteins, etc.). Though most MAA research is done on their photo-protective capabilities, they are also considered to be multi-functional secondary metabolites that have many cellular functions. MAAs are effective antioxidant molecules and are able to stabilize free radicals within their ring structure. In addition to protecting cells from mutation via UV radiation and free radicals, MAAs are able to boost cellular tolerance to desiccation, salt stress, and heat stress.
Sources: en.wikipedia.org
No. Melanotan-2 is manufactured synthetically. The naturally occurring peptide in the same family is alpha-melanocyte-stimulating hormone, which the body produces as part of normal endocrine and neural signalling.
Both are synthetic analogues derived from the same parent hormone. Reference descriptions usually characterise afamelanotide as more selective for the MC1R subtype, whereas melanotan-2 is reported to interact with a wider range of melanocortin receptors.
Early studies explored melanocortin signalling and pigmentation, which later led to informal use of the label tanning peptide. That label is not a regulatory category and does not imply approved status for any purpose.
It is a synthetic cyclic heptapeptide and an analogue of alpha-melanocyte-stimulating hormone. The molecule is produced by chemical synthesis rather than extracted from a biological source.